Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 mai 2024 16h38 HE
|
Vera Therapeutics
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted...
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
02 avr. 2024 08h00 HE
|
Vera Therapeutics
72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02,...
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
20 mars 2024 07h30 HE
|
Vera Therapeutics
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentActively adding sites and...
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
28 févr. 2024 16h20 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
02 févr. 2024 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
01 févr. 2024 16h05 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for...
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
29 janv. 2024 23h50 HE
|
Vera Therapeutics
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
29 janv. 2024 06h15 HE
|
Vera Therapeutics
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for...
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
25 janv. 2024 06h30 HE
|
Vera Therapeutics
– Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment – Placebo cohort...
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
08 janv. 2024 08h01 HE
|
Vera Therapeutics
BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for...